DrugPatentWatch Database Preview
Cetuximab - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for cetuximab
| Tradenames: | 1 |
| Patents: | 620 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for cetuximab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for cetuximab |
Recent Clinical Trials for cetuximab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Yanhong Deng | Phase 3 |
| Medical University of Vienna | Phase 2 |
| Yuhong Li | Phase 2 |
Recent Litigation for cetuximab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ravgen, Inc. v. Natera, Inc. | 2020-06-01 |
| Ravgen, Inc. v. PerkinElmer Inc. | 2020-06-01 |
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| GEMoaB Monoclonals GmbH | 2019-12-20 |
| 2018-09-14 | |
| 2018-01-08 |
Pharmacology for cetuximab
| Mechanism of Action | HER1 Antagonists |
Company Disclosures: US Patents for cetuximab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) | 2018-04-17 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for cetuximab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Yeda Research and Development Co. Ltd. (Rehovot, IL) | 2034-09-08 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW) | 2039-02-26 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | 2030-04-21 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Wake Forest University Health Sciences (Winston-Salem, NC) | 2033-09-13 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for cetuximab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2155786 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007044449 | Start Trial |
| South Korea | 101002443 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008051363 | Start Trial |
| Canada | 2794513 | Start Trial |
| European Patent Office | 1853294 | Start Trial |
| South Africa | 200908454 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for cetuximab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0753 | Netherlands | Start Trial | PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 2016022 | Lithuania | Start Trial | PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321 |
| 2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
| 2015 | Austria | Start Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| 1021 | Netherlands | Start Trial | PRODUCT NAME: TALAZOPARIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1377 20190624 |
| 140 | Estonia | Start Trial | |
| 2015 00006 | Denmark | Start Trial | PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
